Saturday 17 October 2026 Export GMED’s income statement to Excel — free account

Globus Medical, Inc.

Globus Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 16.7% from fiscal 2024. In the quarter to June 2026, revenue grew 5.94%, EPS fell 25.3% and free cash flow grew 571.3%, each against the same quarter a year earlier. Revenue growth for ten consecutive years, operating cash flow growth for three.

76.71 2.13 −2.70%

Follow GMED

Alert me

Market cap: $10.6B
P/E: 19.3×
Fwd P/E: 20.3×
Dividend yield: —
F-score: 9/9
Altman Z: 11.30
Beneish M: −2.31
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 17.54

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	4	2	2	2	—	—	—	1	—	1	1	—

Insider Ownership 17.81%

Capital & Financial Ratios $m

Market Cap 10,590.00

Revenue 3,144.93

Net Income 535.43

Free Cash Flow 755.59

Net Debt (595.14)

Current Ratio 4.62

Debt/Equity 0.00

P/E ratio 19.32

Fwd P/E 20.30

P/S ratio 3.29

P/B ratio 2.17

Past 5Y EPS Growth 31.16%

This Y EPS Growth 25.64%

Next Y EPS Growth 7.98%

Next Y revenue growth 8.88%

Next 5Y EPS Growth 13.83%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 6.78%

10-year low 10-year high

P/S against its own 10 years 5.86%

10-year low 10-year high

P/B against its own 10 years 11.72%

10-year low 10-year high

EV/Sales against its own 10 years 7.41%

10-year low 10-year high

EV/FCF against its own 10 years 2.10%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	518	890	557	595
Receivables	505	578	744	739
Inventory	848	659	759	811
Other	—	—	—	—
	1,915	2,177	2,126	2,216

	2023	2024	2025	Q'26
Payables	57	75	99	107
ST’ Debt	—	443	—	—
Other	61	34	20	23
	392	856	498	479

Compound Annual Growth %

	10y	5y	3y
Sales	18.36%	30.08%	42.17%
Cash Flow	19.77%	30.54%	61.62%
Earnings	16.91%	39.37%	41.42%
Book Value	20.38%	24.87%	35.30%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	760	790	—	—	—
’25	598	745	769	826	2,939
’24	607	630	626	657	2,519
’23	277	292	384	617	1,568
’22	231	264	254	274	1,023
’21	227	251	230	250	958
’20	191	149	216	233	789

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	202	210	—	—	—
’25	177	78	250	249	753
’24	52	54	204	210	521
’23	53	35	50	105	243
’22	45	37	33	64	178
’21	64	59	77	76	276
’20	42	23	53	80	199

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	163	177	—	—	—
’25	136	26	204	202	579
’24	24	26	162	193	405
’23	37	17	29	82	165
’22	25	13	21	46	104
’21	50	51	59	59	219
’20	20	13	36	66	135

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.90	1.10	—	—	—
’25	0.54	1.49	0.88	1.03	3.92
’24	(0.05)	0.23	0.38	0.19	0.75
’23	0.48	0.57	0.01	0.11	1.07
’22	0.37	0.53	0.47	0.49	1.85
’21	0.44	0.40	0.45	0.14	1.44
’20	0.25	(0.21)	0.44	0.52	1.01

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	19.25	24.58	41.19	38.01	33.41	59.37	52.60	43.39	49.33	51.79	Analyst estimates 2026–2028 Powerpack
	High	27.64	42.00	57.83	60.15	66.65	84.23	81.78	80.04	87.22	94.93
People
People	Employees	1,400	1,500	1,800	2,000	2,200	2,400	2,600	5,000	5,300	6,000
	Revenue/emp, $m	0.40	0.42	0.40	0.39	0.36	0.40	0.39	0.31	0.48	0.49
Income, $m
Income, $m	Revenue	564	636	713	785	789	958	1,023	1,568	2,519	2,939
	Gross margin, %	76.12	76.34	77.64	77.08	72.44	75.03	74.22	65.05	58.90	67.41
	EBT	157	170	189	190	126	180	243	165	121	605
	EBT margin, %	27.89	26.72	26.45	24.19	15.96	18.83	23.76	10.54	4.79	20.59
	Net income	104	107	156	155	102	149	190	123	103	538
	Depreciation	46	45	43	52	63	73	74	225	495	303
Per share, $
Per share, $	Revenue	5.90	6.61	7.28	7.92	8.00	9.51	10.18	13.87	18.56	21.74
	Earnings	1.09	1.12	1.60	1.57	1.04	1.48	1.89	1.09	0.76	3.98
	Cash flow	1.55	1.65	1.86	1.73	2.02	2.74	1.78	2.15	3.84	5.57
	Capex	(0.43)	(0.53)	(0.56)	(0.71)	(0.65)	(0.56)	(0.74)	(0.69)	(0.85)	(1.29)
	Free cash flow	1.12	1.12	1.30	1.02	1.37	2.18	1.04	1.46	2.99	4.28
	Book value	8.70	10.06	12.11	14.14	15.28	17.29	18.38	35.35	30.78	33.82
	Shares, m	96	96	98	99	99	101	100	113	136	135
Valuation, ×
Valuation, ×	P/E	22.95	38.54	27.05	37.27	62.71	48.78	38.71	45.05	110.28	21.94
	P/S	4.20	6.53	5.94	7.43	8.15	7.59	7.19	3.83	4.46	4.02
	P/B	2.85	4.29	3.57	4.16	4.27	4.18	3.98	1.50	2.69	2.58
	EV/Sales	3.69	5.95	5.47	7.04	7.61	7.13	6.76	3.78	4.44	4.12
	EV/FCF	19.46	35.09	30.70	54.62	44.46	31.15	66.17	35.86	27.63	21.28
Cash, $m
Cash, $m	Operating cash flow	148	159	182	172	199	276	178	243	521	753
	Capex	(41)	(51)	(55)	(71)	(64)	(57)	(74)	(78)	(115)	(174)
	Free cash flow	107	108	127	101	135	219	104	165	405	579
Balance, $m
Balance, $m	Working capital	434	527	535	576	701	724	824	1,523	1,321	1,627
	Total debt	—	—	—	2	5	5	—	417	443	—
	Net debt	(291)	(374)	(340)	(309)	(422)	(438)	(446)	(100)	(447)	(557)
	Shareholders’ equity	832	968	1,186	1,402	1,506	1,741	1,846	3,998	4,177	4,573
Returns, %
Returns, %	ROA	11.85	10.70	13.15	10.96	6.37	8.20	9.43	3.43	1.99	10.19
	ROIC	17.80	17.03	12.51	9.84	6.42	8.25	10.17	2.14	2.78	7.47
	ROE	13.49	11.93	14.53	11.99	7.03	9.19	10.60	4.20	2.52	12.29

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ZBH Zimmer Biomet Holdings, Inc.	$18.0B	23.0×	17.7×	+4.80% (above 0%: growing)	+33.77% (above 0%: growing)	+13.05% (above 0%: growing)	70.81%	14.98%	Compare
PEN Penumbra, Inc.	$12.7B	78.4×	63.5×	+14.90% (above 0%: growing)	−24.79% (below 0%: shrinking)	+10.81% (above 0%: growing)	67.93%	10.52%	Compare
SNN Smith & Nephew SNATS, Inc.	$12.2B	35.4×	18.6×	+7.99% (above 0%: growing)	−14.23% (below 0%: shrinking)	+293.94% (above 0%: growing)	69.42%	0.00%	Compare
GMED Globus Medical, Inc.	$10.6B	19.3×	20.3×	+5.94% (above 0%: growing)	−25.33% (below 0%: shrinking)	+571.30% (above 0%: growing)	69.42%	23.10%
BIO.B Bio-Rad Laboratories, Inc.	$10.3B	43.7×	—	−0.09% (below 0%: shrinking)	+19.02% (above 0%: growing)	−6.06% (below 0%: shrinking)	53.12%	11.15%	Compare
GKOS Glaukos Corporation	$9.8B	— (loss-making)	— (loss-making)	+49.54% (above 0%: growing)	n/m	+211.83% (above 0%: growing)	81.67%	(9.30%)	Compare
BIO Bio-Rad Laboratories, Inc.	$9.8B	42.5×	35.4×	−0.09% (below 0%: shrinking)	+19.02% (above 0%: growing)	−6.06% (below 0%: shrinking)	53.12%	11.15%	Compare
PODD Insulet Corporation	$9.6B	26.4×	24.7×	+23.51% (above 0%: growing)	+328.13% (above 0%: growing)	−70.51% (below 0%: shrinking)	70.18%	16.18%	Compare
BRKR Bruker Corporation	$8.6B	— (loss-making)	55.7×	+5.15% (above 0%: growing)	n/m	+28.63% (above 0%: growing)	49.61%	(7.79%)	Compare
Median of peers	$10.0B	38.9×	30.0×	+6.57%	+19.02%	+11.93%	68.68%	10.84%

All 149 Medical Devices stocks →

Globus Medical, Inc. (GMED) key facts

Strength: Globus Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 16.7% from fiscal 2024.
Strength: Net income was $537.9 million, or $3.98 per share (basic), a net margin of 18.3%.
Globus Medical, Inc. (GMED) is a Medical Devices company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, GMED traded at $76.71, a market capitalization of $10.6 billion.
At that price the stock trades at 19.3× trailing-twelve-month earnings and 3.3× sales; its P/E is higher than 7% of its own readings over the past ten years.
Return on equity was 12.3% and debt-to-equity 0.00.
Its Piotroski F-score is 9 out of 9 and its Altman Z-score is 11.30 (safe zone) for fiscal 2025.